COVID

Viral kinetics and antibody responses in patients with COVID-19

Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT1

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Mansoura faculty of medicine

Post Covid-19 Cardiopulmonary and Immunological Changes

Cardiopulmonary and Immunological Impacts of Covid-19 in a Cohort of Survivors

pulmonary function include lung volumes in millimetre and lung capacities

Ejection fraction ,myocardial contractility,pulmonary artery pressure

IGG,IGM level using rapid covid antibody titre

no plan for sharing data for other researchers

Mansoura University

500 ug tablet daily for 180 days
Roflumilast: PDE4 inhibitor

Roflumilast

Placebo 1 tablet daily x 180 days
Placebo: Inactive substance.

Placebo

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

A combined endpoint of time to all-cause mortality or re-hospitalization during the 180 days post-randomization was used.

Time to All-cause Mortality or Re-hospitalization During the 180 Days Post-randomization.

respiratory death or respiratory re-hospitalization during the 180 days post-randomization; rate of death or readmission during the 30 days post-discharge; treatment failure (see definition below); change in health status, FEV1 (forced expiratory volume at one second, and dyspnea during the 180 days post-randomization; length of hospital stay during the index hospitalization.

Respiratory Death or Respiratory Re-hospitalization

Reported adverse events during the course of the study. Need to withdraw study drug due to adverse events

Assess Tolerance of Roflumilast vs. Placebo in Hospitalized AECOPD

Overall Study

Michael R. Jacobs - Director of Research Development

COPD

Temple University Hospital

Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization

Effects of Roflumilast in Hospitalized COPD on Mortality and Re-hospitalization

Final data will be in a de-identified computerized dataset maintained by the investigators at Temple University. De-identified data will be shared through either password protected website maintained without cost to researchers after requests are vetted by principal investigators at Temple University.

bronchiectasis/edema

Post Covid-19 Cardiopulmonary and Immunological Changes

Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization

La base de dades d’herbes medicinals més completa avalada per la ciència